文献速递胃肠动力与功能性疾病消化内镜

胃经口内镜下肌切开术在不同病因胃轻瘫中的疗效与安全性:系统评价与Meta分析

Efficacy and safety of gastric peroral endoscopic myotomy across different etiologies of gastroparesis: systematic review and meta-analysis.
PubMed 文献 · Gastrointest Endosc · 2024-08-23

该系统评价与Meta分析纳入15项研究共982例患者,评估胃经口内镜下肌切开术(G-POEM)按胃轻瘫病因分层的疗效与安全性。术后病因临床成功率65%(95%CI 51-77;I2=46%),术后状态70%(95%CI 46-86;I2=73%),特发性60%(95%CI 41-77;I2=68%)。G-POEM在不同病因的难治性胃轻瘫中均有效且安全,胃轻瘫症状指数(GCSI)评分显著改善。

要点

  • 术后病因临床成功率65%(95%CI 51-77;I2=46%),术后状态70%(95%CI 46-86;I2=73%),特发性60%(95%CI 41-77;I2=68%)。
  • GCSI评分改善:糖尿病组1.7(95%CI -0.01至3.5;P=0.052),术后状态组1.34(95%CI -0.07至2.62;P=0.038),特发性组1.5(95%CI 0.36-2.75;P=0.01)。
  • G-POEM对难治性胃轻瘫无论病因均有效且安全。

核心结论

  • 基于本Meta分析,G-POEM治疗难治性胃轻瘫不受病因影响均有效且安全,临床成功率和GCSI评分均显著改善。

研究设计与样本

  • 系统评价与Meta分析,纳入15项研究(7项回顾性、8项前瞻性),共982例患者(平均年龄50.81岁;平均随访21个月)。
  • 检索主要数据库截至2023年10月,按病因评估G-POEM的疗效与安全性,采用随机效应模型,异质性用I2统计量评估。

主要发现

  • 术后状态是最常见病因(290例),其次为特发性(287例)和糖尿病(286例)。
  • 临床成功率:糖尿病65%(95%CI 51-77;I2=46%),术后状态70%(95%CI 46-86;I2=73%),特发性60%(95%CI 41-77;I2=68%)。
  • GCSI评分改善:糖尿病1.7(95%CI -0.01至3.5;P=0.052),术后状态1.34(95%CI -0.07至2.62;P=0.038),特发性1.5(95%CI 0.36-2.75;P=0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Gastric peroral endoscopic myotomy (G-POEM) is an emerging treatment for refractory gastroparesis. Although its efficacy and safety have been analyzed in previous systematic reviews and meta-analyses, no studies have compared its effectiveness based on etiology. Our study aims to evaluate the efficacy and safety of G-POEM by etiologies of gastroparesis. METHODS: We conducted a comprehensive search in major databases until October 2023, focusing on the efficacy and safety of G-POEM by etiology. Our primary outcome was clinical success based on etiology, with an additional subgroup analysis on Gastroparesis Cardinal Symptom Index (GCSI) scores before and after G-POEM based on etiology using standard meta-analysis methods and the random-effects model. Heterogeneity was assessed using I2 statistics. RESULTS: In our analysis of 15 studies (7 retrospective, 8 prospective) involving 982 patients (mean patient age, 50.81 years; mean follow-up, 21 months), postsurgical conditions were the most common etiology in G-POEM (290 cases), followed by idiopathic factors (287 cases) and diabetes (286 cases). Subgroup analysis revealed pooled clinical success rates of 65% (95% confidence interval [CI], 51-77; I2 = 46%) for diabetes, 70% (95% CI, 46-86; I2 = 73%) for postsurgical conditions, and 60% (95% CI, 41-77; I2 = 68%) for idiopathic etiologies. Our research also indicated that G-POEM significantly improved GCSI scores: 1.7 (95% CI, -.01 to 3.5; P = .052) for diabetes, 1.34 (95% CI, -.07 to 2.62; P = .038) for postsurgical conditions, and 1.5 (95% CI, .36-2.75; P = .01) for idiopathic patients. CONCLUSIONS: Based on this meta-analysis, G-POEM is effective and safe for treating refractory gastroparesis irrespective of the etiology, with significant improvements in clinical success rates and GCSI scores.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Malik S, Loganathan P, Khan K, et al. Efficacy and safety of gastric peroral endoscopic myotomy across different etiologies of gastroparesis: systematic review and meta-analysis. Gastrointest Endosc. 2024. PMID: 39181473. doi:10.1016/j.gie.2024.08.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。